13 results about "Peptide Synthetases" patented technology

The invention relates to the technical field of biosynthesis, and particularly discloses a pyridone compound as well as a biosynthesis method and application thereof. On the basis of related technologies of synthetic biology, non-ribosome peptide synthetase is modified, non-ribosome peptide synthetase mutants are heterologously expressed in various hosts, a pyridone compound is found and obtained for the first time, the chemical molecular formula of the pyridone compound is determined to be C5H4N2O3, and the pyridone compound is named as 5-aminopyridine-2, 3, 6-triketone or 5-hydroxy-3-iminopyridine-2, 3, 6-triketone or 5-hydroxy-3-iminopyridine-2, 3, 6-triketone or 5-hydroxy-3-iminopyridine-2, 3, 6-triketone. The novel pyridone compound can be used as a raw material or an intermediate to be applied to development and preparation of novel antibiotics, drugs and dyes.

This application relates to the field of biosynthesis technology, and specifically discloses a pyridone compound, its biosynthesis method and application. Based on synthetic biology-related technologies, this application modifies non-ribosomal peptide synthetase, heterologously expresses non-ribosomal peptide synthetase mutants in a variety of hosts, and for the first time discovers and obtains a pyridone compound, and determines its chemical formula as C5H4N2O3, named 5-amino-pyridine-2,3,6-trione or 5-hydroxy-3-imino-pyridine-2,6-dione. This novel pyridone compound can be used as a raw material or intermediate in the development and preparation of novel antibiotics, drugs and dyes.

The present disclosure pertains to produce a novel NRPS. In the present disclosure, a restriction enzyme recognition sequence was successfully introduced into a nucleic acid encoding an NRPS while maintaining a function of producing a target NRP. Various NRPSs can be produced using the introduced restriction enzyme recognition sequence. In one aspect, the present disclosure provides a nucleic acid containing a non-native restriction enzyme recognition sequence and encoding an NRPS. In another aspect, the present disclosure provides a method for efficiently producing a nucleic acid encoding a novel NRPS using a non-native restriction enzyme recognition sequence. In addition, the present disclosure also provides a novel NRPS and a novel NRP.

This invention discloses a Bacillus bellis strain overexpressing a lipopeptide synthase gene, its construction method, and its application in fruit preservation. It belongs to the fields of microbial genetic engineering and postharvest fruit preservation technology. Using Bacillus bellis QB250122 as the starting strain, two rounds of genome editing were performed using a dual-plasmid temperature-sensitive CRISPR-Cas9n system. In the first round, the srfA promoter was replaced with the PHpaII superpromoter. In the second round, a complete expression cassette was inserted at the bacA site. The engineered strain produced 900-1200 mg / L of surfactantin. Applying a bacterial suspension to the surface of fruits such as mangoes can extend shelf life by 10-15 days.

The invention relates to the field of medicinal chemistry, and relates to a small molecule peptide for inhibiting growth of staphylococcus, and an analogue and application thereof. The method comprises the following steps: finding a rhodococcus genome from an NCBI (National Center of Biotechnology Information) microbial genome database, and predicting a non-ribosome peptide structure synthesized by a non-ribosome peptide synthetase (NRPS) sequence through software such as AntiSMASH and Prism; the method comprises the following steps: classifying all NRPS biosynthetic gene clusters (BGCs) through Bigscape to obtain a gene cluster family (GCFs); the method comprises the following steps: predicting the selectivity of a GCFs substrate and screening a polypeptide with antibacterial potential through Phammapper; a small molecule peptide (compound I) is obtained through chemical synthesis, and the small molecule peptide is found to have an inhibition effect on staphylococcus epidermidis and staphylococcus pseudointermedius; afterwards, alanine is used for replacing glutamine to increase hydrophobicity of glutamine (compound II), the antibacterial effect of the compound II is obviously enhanced, and the compound II has the potential of developing novel antibacterial drugs and biopesticides.

The invention belongs to the technical field of genetic engineering and synthetic biology, and particularly relates to a discontinuous paired homologous arm mediated Red / ET homologous recombination method and application thereof. According to the method, a discontinuous paired homologous arm mediated homologous recombination engineering technology is utilized, and the method is essentially different from traditional Red / ET type recombinase mediated continuous homologous arm homologous recombination. Experiments prove that the method can be applied to modular gene cluster transformation of non-ribosome polypeptide synthetase (NRPS), the transformation efficiency of the NRPS is remarkably improved, the transformation success rate of natural products synthesized by the NRPS is further greatly improved, and a key technical support is provided for fully releasing the application potential of the active natural products. Therefore, the method is not only an innovation and an effective supplement of the existing Red / ET class editing method, but also an ideal expansion of the current genetic engineering technology system, and has good practicability and wide application value.

The invention discloses an engineering strain and application of the engineering strain in preparation of pneumocandin. The engineering strain does not express a GloA-A2 gene, and expresses a non-ribosomal peptide synthetase gene CENRPS-A2 or CCNRPS-A2, so that the proportion of PB0-ser in a fermentation product can be adjusted, the generation of PB0-ser and PB0 is controlled from the source, and the cost for separating PB0-ser and PB0 is reduced.

The application discloses an amino acid sequence of tranexamic acid-carnosine ligase, and a preparation method of tranexamic acid-carnosine conjugate. The amino acid sequence of the tranexamic acid-carnosine ligase is shown as SEQ ID NO: 4. The tranexamic acid-carnosine ligase is fused by an adenylation (A) domain, a thioesterification (T) domain and a condensation (C) domain. The adenylation domain is obtained by mutation and modification of an adenylation domain in non-ribosomal peptide synthetase from Streptomyces coelicolor. After the mutation and modification, the adenylation domain has high specificity for a substrate tranexamic acid, can efficiently recognize and activate the tranexamic acid, so that the tranexamic acid-carnosine ligase can efficiently catalyze the reaction of the tranexamic acid and L-carnosine to generate the tranexamic acid-carnosine conjugate.

The present invention relates to the field of medicinal chemistry and relates to a small molecule peptide with anti-cancer activity and its application. By analyzing the non-ribosomal peptide synthetase (NRPS) sequence of a Rhodococcus erythropolis strain using bioinformatics software, the possible molecular backbone of the non-ribosomal peptide synthesized by this NRPS was predicted, and a series of small molecule peptides were obtained through chemical synthesis. After activity testing, one of the small molecule peptides was screened out to have a relatively obvious inhibitory effect on the cancer cell line HT29, and it has the value for the development of new anti-cancer drugs.

The present invention provides a chimeric polyketide synthase (PKS) or polyketide synthase-non-ribosomal peptide synthetase (PKS-NRPS) and the use thereof, wherein the PKS or PKS-NRPS comprises two or more recombination units (RU) which are joined to each other, wherein each RU comprises one or two or more contiguous domains derived from a parental PKS or PKS-NRPS and the junction end of at least one RU is defined by a recombination site selected from a site at the LPTY (A / P) FQ (H / R) xRYWL motif at post AT-linker (the RYWL motif site) and a site at the RL motif at ACP helix 0 (the RL motif site); wherein the two or more RUs are not naturally joined with each other.

This invention discloses a bacterial strain and method for producing notoginseng extract, belonging to the field of bioengineering technology. This invention constructs recombinant cells or combinations of recombinant cells expressing alcohol dehydrogenase, amine dehydrogenase, ATP-dependent peptide synthase, polyphosphokinase 2-I, and polyphosphokinase 2-II, or replaces polyphosphokinase 2-I and polyphosphokinase 2-II with polyphosphokinase 2-III. The recombinant cells or combinations of recombinant cells are used to catalyze the synthesis of notoginseng extract from serine and oxalic acid. Using 100 g / L L-serine as a substrate, a maximum yield of 173 g / L L-notoginseng extract can be obtained. Therefore, this invention has good prospects for industrial application.

The present invention provides a genetically modified host cell capable of producing Porphyra-334 and / or Shinorine, which comprises (a) (i) a 2-demethyl-4-deoxycod's alcohol synthase (DDGS), (ii) an O-methyltransferase (O-MT or OMT), (iii) an ATP dependent carboxylic acid-amine ligase, and (iv) a non-ribosomal peptide synthetase (NRPS) or a D-ala-D-ala ligase, MysD or MysE; or (b) MysA, MysB, MysC or MysD, MysE or NRPS; wherein one or more of the foregoing enzymes are their homologous enzymes.

The invention relates to a novel NRPS. In the present invention, a restriction enzyme recognition sequence is successfully introduced into a nucleic acid encoding an NRPS while maintaining the function of producing an NRP of interest. Various NRPS can be produced using the introduced restriction enzyme recognition sequence. In one aspect, the present invention provides NRPS-encoding nucleic acids comprising a non-natural restriction enzyme recognition sequence. In other aspects, the present invention provides a method for efficiently producing a nucleic acid encoding a novel NRPS using a non-natural restriction enzyme recognition sequence. In addition, the present invention also provides a novel NRPS and a novel NRP.